The clinical trials involving the molecule are currently in phase II stage for keratosis (a particular kind of skin damage induced by the UV exposure) and the more severe squamous cell carcinoma and in phase III stage for the mitigation of polymorphous light eruption
potential data that would have been collected after the occurrence of intercurrent events, if participants had not had intercurrent events, were imputed implicitly
12 weeks 17 vials (10 mg) 84 daily doses needed
Expression of the Glucagon-Like Peptide-1 Receptor and Its Role in Regulating Autophagy in Endometrial Cancer
Spiering BA, Kraemer WJ, Vingren JL, Hatfield DL, Fragal MS, Ho JY, Maresh CM, Anderson JM, Volek JS